Map metabolic dependencies in the patient, not the dish
Metabolic drugs keep failing because tumours switch fuels. Measuring what a patient's tumour actually eats, with tracers and PET, could pick the right metabolic drug for the right tumour.
Isotope tracing in patients (DeBerardinis) shows in vivo fuel use differs from culture; FDG, glutamine (18F-FGln), and acetate PET tracers exist; glutaminase and other agents failed in unselected populations.
Pages like this
not linked directly; found by shared links- IdeaCut the nerve supply to tumours with old drugs
Shares MD Anderson Cancer Center, Memorial Sloan Kettering Cancer Center, Glioma & glioblastoma and the tags mechanism, open-question.
- IdeaMicrobiome transplant as a routine immunotherapy adjunct
Shares MD Anderson Cancer Center, Non-small-cell lung cancer and the tags mechanism, open-question.
- IdeaGive immunotherapy in the morning
Shares Memorial Sloan Kettering Cancer Center, Non-small-cell lung cancer and the tags mechanism, open-question.
- IdeaIs aneuploidy itself a druggable vulnerability?
Shares Memorial Sloan Kettering Cancer Center and the tags mechanism, open-question.
- IdeaWhat makes a neoantigen actually immunogenic?
Shares Memorial Sloan Kettering Cancer Center and the tags mechanism, open-question.
- IdeaOne-two punch: clear senescent cells after chemotherapy
Shares Memorial Sloan Kettering Cancer Center and the tags mechanism, open-question.
- IdeaShared splice-derived neoantigens as off-the-shelf vaccine targets
Shares Memorial Sloan Kettering Cancer Center and the tags mechanism, open-question.
- IdeaWhich patients' blood clones will become leukaemia after treatment?
Shares Memorial Sloan Kettering Cancer Center and the tags mechanism, open-question.